Renal Failure - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 41 pages report, published by Global Markets Direct

Keywords : Renal Failure Therapeutic Products under Development, Key Players in Renal Failure Therapeutics, Renal Failure Pipeline Overview, Renal Failure Pipeline, Renal Failure Pipeline Assessment

Report ThumbnailSeptember-2013
Renal Failure - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Renal Failure - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Renal Failure, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Renal Failure. Renal Failure - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Renal Failure.
- A review of the Renal Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Renal Failure pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Renal Failure.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Renal Failure pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Renal Failure, H2 2013 7
  • Products under Development for Renal Failure - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 10
  • Mid Clinical Stage Products, H2 2013 11
  • Early Clinical Stage Products, H2 2013 12
  • Discovery and Pre-Clinical Stage Products, H2 2013 13
  • Assessment by Monotherapy Products, H2 2013 18
  • Assessment by Combination Products, H2 2013 19
  • Assessment by Route of Administration, H2 2013 20
  • Assessment by Stage and Route of Administration, H2 2013 21
  • Assessment by Molecule Type, H2 2013 22
  • Assessment by Stage and Molecule Type, H2 2013 23
  • List of Tables
  • Number of Products Under Development for Renal Failure, H2 2013 7
  • Products under Development for Renal Failure - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Number of Products under Investigation by Universities/Institutes, H2 2013 10
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 12
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 13
  • Products under Development by Companies, H2 2013 14
  • Products under Investigation by Universities/Institutes, H2 2013 15
  • La Jolla Pharmaceutical Company, H2 2013 16
  • Virobay Inc., H2 2013 17
  • Assessment by Monotherapy Products, H2 2013 18
  • Assessment by Combination Products, H2 2013 19
  • Assessment by Stage and Route of Administration, H2 2013 21
  • Assessment by Stage and Molecule Type, H2 2013 23
  • Renal Failure Therapeutics - Drug Profile Updates 34
  • Renal Failure Therapeutics - Dormant Products 37
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Renal Failure Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Renal Failure 7
  • Renal Failure Therapeutics under Development by Companies 9
  • Renal Failure Therapeutics under Investigation by Universities/Institutes 10
  • Mid Clinical Stage Products 11
  • Comparative Analysis 11
  • Early Clinical Stage Products 12
  • Comparative Analysis 12
  • Discovery and Pre-Clinical Stage Products 13
  • Comparative Analysis 13
  • Renal Failure Therapeutics - Products under Development by Companies 14
  • Renal Failure Therapeutics - Products under Investigation by Universities/Institutes 15
  • Companies Involved in Renal Failure Therapeutics Development 16
  • La Jolla Pharmaceutical Company 16
  • Virobay Inc. 17
  • Renal Failure - Therapeutics Assessment 18
  • Assessment by Monotherapy Products 18
  • Assessment by Combination Products 19
  • Assessment by Route of Administration 20
  • Assessment by Molecule Type 22
  • Drug Profiles 24
  • GCS-100 - Drug Profile 24
  • Product Description 24
  • Mechanism of Action 24
  • R&D Progress 24
  • DAA-I - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • albumin human + midodrine hydrochloride + octreotide - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • Pathfinder Cells - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • VBY-X - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • Ixac - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • Aquaporin Modulators - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • Renal Failure Therapeutics - Drug Profile Updates 34
  • Renal Failure Therapeutics - Dormant Products 37
  • Renal Failure - Product Development Milestones 38
  • Featured News & Press Releases 38
  • Feb 05, 2013: La Jolla Pharma Receives Notice Of Allowance For Patent Covering Modified Pectin Compositions 38
  • Jul 24, 2012: BioCryst Pharma Announces Positive Results From Two Ulodesine Phase II Trials In Patients With Gout 38
  • Appendix 40
  • Methodology 40
  • Coverage 40
  • Secondary Research 40
  • Primary Research 40
  • Expert Panel Validation 40
  • Contact Us 41
  • Disclaimer 41

Please select a license type

Share

Related Products

Global Markets DirectRenal Failure - Pipeline Review, H2 2013Product ThumbnailRenal Failure - Pipeline Review, H2 2013, Industry ReportProduct #: 113346
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved